$NTRA
Natera, Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024011666 Filed on August 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $439.8M $413.4M
YoY Change 63.9% 58.13%
Cost Of Revenue $168.0M $170.2M
YoY Change 14.06% 18.88%
Gross Profit $271.7M $243.2M
YoY Change 124.58% 105.63%
Gross Profit Margin 61.79% 58.83%
Selling, General & Admin $214.2M $198.0M
YoY Change 38.39% 29.81%
% of Gross Profit 78.81% 81.41%
Research & Development $96.93M $89.11M
YoY Change 25.5% 13.99%
% of Gross Profit 35.67% 36.64%
Depreciation & Amortization $8.200M $7.915M
YoY Change 17.31% 54.47%
% of Gross Profit 3.02% 3.25%
Operating Expenses $311.1M $287.1M
YoY Change 34.1% 24.45%
Operating Profit -$39.34M -$43.90M
YoY Change -64.55% -60.95%
Interest Expense $3.142M $3.127M
YoY Change -3.38% -198.43%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$30.86M -$36.57M
YoY Change -71.64% -67.08%
Income Tax $730.0K $892.0K
% Of Pretax Income
Net Earnings -$31.59M -$37.46M
YoY Change -71.02% -66.19%
Net Earnings / Revenue -7.18% -9.06%
Basic Earnings Per Share -$0.26 -$0.30
Diluted Earnings Per Share -$0.26 -$0.30
COMMON SHARES
Basic Shares Outstanding 123.7M 122.8M
Diluted Shares Outstanding 123.8M 122.9M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $922.3M $887.1M
YoY Change -1.53% 20.54%
Cash & Equivalents $892.8M $796.8M
Short-Term Investments $29.49M $90.30M
Other Short-Term Assets $44.63M $37.80M
YoY Change 33.23% 40.94%
Inventory $48.72M $40.99M
Prepaid Expenses
Receivables $306.9M $335.9M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.323B $1.302B
YoY Change 4.36% 22.18%
LONG-TERM ASSETS
Property, Plant & Equipment $142.2M $133.3M
YoY Change 35.62% -19.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $38.36M $29.31M
YoY Change 136.65% 67.32%
Total Long-Term Assets $268.4M $215.2M
YoY Change 49.73% 17.98%
TOTAL ASSETS
Total Short-Term Assets $1.323B $1.302B
Total Long-Term Assets $268.4M $215.2M
Total Assets $1.591B $1.517B
YoY Change 9.98% 21.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $27.83M $33.10M
YoY Change 30.55% 56.82%
Accrued Expenses $159.4M $166.3M
YoY Change 1.62% 15.29%
Deferred Revenue $17.89M $18.37M
YoY Change 19.14% 17.41%
Short-Term Debt $80.47M $80.40M
YoY Change 0.09% -0.02%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $301.4M $314.6M
YoY Change 3.96% 13.62%
LONG-TERM LIABILITIES
Long-Term Debt $286.5M $283.6M
YoY Change 1.4% 0.46%
Other Long-Term Liabilities $124.5M $82.29M
YoY Change 39.37% -11.13%
Total Long-Term Liabilities $411.0M $365.9M
YoY Change 10.52% -2.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $301.4M $314.6M
Total Long-Term Liabilities $411.0M $365.9M
Total Liabilities $712.4M $680.5M
YoY Change 7.64% 4.41%
SHAREHOLDERS EQUITY
Retained Earnings -$2.500B -$2.500B
YoY Change 8.7% 13.64%
Common Stock $3.393B $3.320B
YoY Change 9.84% 18.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $878.5M $836.5M
YoY Change
Total Liabilities & Shareholders Equity $1.591B $1.517B
YoY Change 9.98% 21.56%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$31.59M -$37.46M
YoY Change -71.02% -66.19%
Depreciation, Depletion And Amortization $8.200M $7.915M
YoY Change 17.31% 54.47%
Cash From Operating Activities $51.79M $3.990M
YoY Change -275.25% -105.09%
INVESTING ACTIVITIES
Capital Expenditures $16.31M $11.68M
YoY Change 79.25% 30.22%
Acquisitions
YoY Change
Other Investing Activities $58.85M -$20.38M
YoY Change -34.79% -136.38%
Cash From Investing Activities $42.54M -$32.05M
YoY Change -47.58% -168.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.720M 11.04M
YoY Change -99.27% 18.6%
NET CHANGE
Cash From Operating Activities 51.79M 3.990M
Cash From Investing Activities 42.54M -32.05M
Cash From Financing Activities 1.720M 11.04M
Net Change In Cash 96.05M -17.02M
YoY Change -66.61% -22.78%
FREE CASH FLOW
Cash From Operating Activities $51.79M $3.990M
Capital Expenditures $16.31M $11.68M
Free Cash Flow $35.47M -$7.688M
YoY Change -191.78% -91.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
123365000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119581000
dei Entity Registrant Name
EntityRegistrantName
Natera, Inc.
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Central Index Key
EntityCentralIndexKey
0001604821
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Shell Company
EntityShellCompany
false
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.20
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122853000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113690000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
121834000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112734000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Entity File Number
EntityFileNumber
001-37478
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
01-0894487
dei Entity Address Address Line1
EntityAddressAddressLine1
13011 McCallen Pass
dei Entity Address Address Line2
EntityAddressAddressLine2
Building A Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78753
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
980-9190
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
NTRA
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
123681432
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
796798000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
642095000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
90299000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
236882000
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
7021000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6481000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
335936000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
278289000
CY2024Q2 us-gaap Inventory Net
InventoryNet
40985000
CY2023Q4 us-gaap Inventory Net
InventoryNet
40759000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
37798000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
60524000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1301816000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1258549000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
133280000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111210000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
52582000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
56537000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29311000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15403000
CY2024Q2 us-gaap Assets
Assets
1516989000
CY2023Q4 us-gaap Assets
Assets
1441699000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
33100000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14998000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
41487000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
45857000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
141231000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
149405000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
18367000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16612000
CY2024Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
80389000
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
80402000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
314574000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
307274000
CY2024Q2 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
283604000
CY2023Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
282945000
CY2024Q2 ntra Contract With Customer And Other Liabilities Noncurrent
ContractWithCustomerAndOtherLiabilitiesNoncurrent
21066000
CY2023Q4 ntra Contract With Customer And Other Liabilities Noncurrent
ContractWithCustomerAndOtherLiabilitiesNoncurrent
19128000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61225000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
67025000
CY2024Q2 us-gaap Liabilities
Liabilities
680469000
CY2023Q4 us-gaap Liabilities
Liabilities
676372000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
123365000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119581000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3320365000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3145837000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2482499000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2377436000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1358000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3085000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
836520000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
765327000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1516989000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1441699000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
413351000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
261404000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
781092000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
503160000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
89109000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78173000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
177746000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
160479000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
197965000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
152508000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
392243000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
302135000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
457253000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
373830000
us-gaap Costs And Expenses
CostsAndExpenses
899308000
us-gaap Costs And Expenses
CostsAndExpenses
753887000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-43902000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-112426000
us-gaap Operating Income Loss
OperatingIncomeLoss
-118216000
us-gaap Operating Income Loss
OperatingIncomeLoss
-250727000
CY2024Q2 us-gaap Interest Expense
InterestExpense
3127000
CY2023Q2 us-gaap Interest Expense
InterestExpense
3177000
us-gaap Interest Expense
InterestExpense
6251000
us-gaap Interest Expense
InterestExpense
6238000
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10457000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4518000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
20724000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
9103000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36572000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-111085000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103743000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-247862000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
892000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-282000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1320000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-122000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-37464000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-110803000
us-gaap Net Income Loss
NetIncomeLoss
-105063000
us-gaap Net Income Loss
NetIncomeLoss
-247740000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
834000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2595000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1727000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
7159000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36630000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108208000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-103336000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-240581000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.20
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122853000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113690000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121834000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112734000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
650573000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
638000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8674000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
44470000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
2595000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-110803000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
596147000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
705744000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2939000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8674000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
19771000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
14435000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
85165000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
7159000
us-gaap Net Income Loss
NetIncomeLoss
-247740000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
596147000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
794111000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2182000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8862000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
67995000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
834000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-37464000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
836520000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
765327000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8648000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8862000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
24071000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
132947000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
1727000
us-gaap Net Income Loss
NetIncomeLoss
-105063000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
836520000
us-gaap Profit Loss
ProfitLoss
-105063000
us-gaap Profit Loss
ProfitLoss
-247740000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14978000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10201000
ntra Expensed In Process Research And Development
ExpensedInProcessResearchAndDevelopment
2679000
ntra Premium Amortization And Discount Accretion On Investment Securities
PremiumAmortizationAndDiscountAccretionOnInvestmentSecurities
-556000
ntra Premium Amortization And Discount Accretion On Investment Securities
PremiumAmortizationAndDiscountAccretionOnInvestmentSecurities
1450000
us-gaap Share Based Compensation
ShareBasedCompensation
131858000
us-gaap Share Based Compensation
ShareBasedCompensation
84789000
us-gaap Operating Lease Cost
OperatingLeaseCost
7204000
us-gaap Operating Lease Cost
OperatingLeaseCost
7451000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
658000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
642000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-377000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-265000
ntra Non Cash Interest Expense
NonCashInterestExpense
-13000
ntra Non Cash Interest Expense
NonCashInterestExpense
68000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
57647000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
15680000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
225000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7281000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-20874000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-12590000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
16668000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9018000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
19701000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
9936000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-8269000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5196000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-10598000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-11175000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1044000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6368000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
30991000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-159651000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
72810000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
221500000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
83250000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31993000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20190000
ntra Payments To Acquire Assets
PaymentsToAcquireAssets
10495000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
106202000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
63060000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8648000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2939000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
8862000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
8674000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17510000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11613000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
154703000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-84978000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
642095000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
466091000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
796798000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
381113000
us-gaap Interest Paid Net
InterestPaidNet
5592000
us-gaap Interest Paid Net
InterestPaidNet
5596000
ntra Purchases Of Property And Equipment In Accounts Payable And Accruals
PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals
2245000
ntra Purchases Of Property And Equipment In Accounts Payable And Accruals
PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals
103000
ntra Acquisition Of Warrants
AcquisitionOfWarrants
1884000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
1400000
us-gaap Stock Issued1
StockIssued1
14435000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
24071000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
19771000
ntra Stock Based Compensation Included In Capitalized Software Development Costs
StockBasedCompensationIncludedInCapitalizedSoftwareDevelopmentCosts
1089000
ntra Stock Based Compensation Included In Capitalized Software Development Costs
StockBasedCompensationIncludedInCapitalizedSoftwareDevelopmentCosts
376000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Net Income Loss
NetIncomeLoss
-105100000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2500000000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
796800000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
90300000
CY2024Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
80400000
CY2024Q2 us-gaap Debt Instrument Collateral Amount
DebtInstrumentCollateralAmount
150000000.0
CY2024Q2 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
20000000.0
CY2023Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
235800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The preparation of financial statements in accordance with generally accepted accounting principles (GAAP) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts, the operating right-of-use assets and the associated lease liabilities, the average useful life for property and equipment including impairment estimates, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of options, income tax uncertainties, and the expected consideration to be received from contracts with customers, insurance payors, and patients. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p>
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2192000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11798000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3085000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16362000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1358000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9203000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1358000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9203000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, and restricted cash, accounts receivable and investments. The Company limits its exposure to loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits of $250,000 per customer. The Company performs evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">For the three and six months ended June 30, 2024, and 2023, there were no customers exceeding 10% of total revenues on an individual basis. As of June 30, 2024 and December 31, 2023, there were no customers with an outstanding balance exceeding 10% of net accounts receivable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">For the three months ended June 30, 2024 and 2023, approximately 10.3% and 12.5%, respectively, of total revenue were paid by Medicare on behalf of multiple customers. For the six months ended June 30, 2024 and 2023, approximately 10.9% and 13.2%, respectively, of total revenue were paid by Medicare on behalf of multiple customers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">As of June 30, 2024 and December 31, 2023, approximately 8.8% and 10.2%, respectively, of accounts receivable are expected to be paid by Medicare on behalf of multiple customers.</p>
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1300000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
413351000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
261404000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
781092000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
503160000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
413351000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
261404000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
781092000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
503160000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
335936000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
278289000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
18367000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16612000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
18416000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
19128000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36783000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
35740000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
35740000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30778000
ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
14826000
ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
17402000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-9646000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-7521000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-4137000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-3513000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36783000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
37146000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-9600000
CY2024Q2 ntra Cash Cash Equivalents Restricted Cash And Securities Amortized Cost Basis
CashCashEquivalentsRestrictedCashAndSecuritiesAmortizedCostBasis
888277000
CY2024Q2 ntra Cash Cash Equivalents Restricted Cash And Securities Accumulated Gross Unrealized Loss
CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedLoss
1180000
CY2024Q2 ntra Cash Cash Equivalents Restricted Cash And Securities
CashCashEquivalentsRestrictedCashAndSecurities
887097000
CY2023Q4 ntra Cash Cash Equivalents Restricted Cash And Securities Amortized Cost Basis
CashCashEquivalentsRestrictedCashAndSecuritiesAmortizedCostBasis
881708000
CY2023Q4 ntra Cash Cash Equivalents Restricted Cash And Securities Accumulated Gross Unrealized Gain
CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedGain
14000
CY2023Q4 ntra Cash Cash Equivalents Restricted Cash And Securities Accumulated Gross Unrealized Loss
CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedLoss
2745000
CY2023Q4 ntra Cash Cash Equivalents Restricted Cash And Securities
CashCashEquivalentsRestrictedCashAndSecurities
878977000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
796798000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
642095000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
90299000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
236882000
CY2024Q2 ntra Cash Cash Equivalents Restricted Cash And Securities
CashCashEquivalentsRestrictedCashAndSecurities
887097000
CY2023Q4 ntra Cash Cash Equivalents Restricted Cash And Securities
CashCashEquivalentsRestrictedCashAndSecurities
878977000
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Securities Sold
DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold
0
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
15
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
23923000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
66376000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1180000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
90299000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1180000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
75440000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
75003000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
16039000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
15296000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
91479000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
90299000
CY2024Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
7252000
CY2023Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
5134000
CY2024Q2 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
185000
CY2023Q2 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-446000
CY2024Q2 us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
46000
CY2024Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
7021000
CY2023Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
5580000
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6481000
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
3830000
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-744000
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-1750000
us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
204000
CY2024Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
7021000
CY2023Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
5580000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
197740000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
167503000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
64460000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
56293000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
133280000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111210000
us-gaap Depreciation
Depreciation
13300000
us-gaap Depreciation
Depreciation
10200000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q2 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
16465000
CY2023Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
23245000
CY2024Q2 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
10574000
CY2023Q4 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
14823000
CY2024Q2 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
14142000
CY2023Q4 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
11229000
CY2024Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
11792000
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
10085000
CY2024Q2 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
13899000
CY2024Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
31979000
CY2023Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
43897000
CY2024Q2 ntra Accrued Shipping Charges
AccruedShippingCharges
1800000
CY2023Q4 ntra Accrued Shipping Charges
AccruedShippingCharges
3646000
CY2024Q2 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
4053000
CY2023Q4 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
3731000
CY2024Q2 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
8173000
CY2023Q4 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
7111000
CY2024Q2 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
7502000
CY2023Q4 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
12126000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12384000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11621000
CY2024Q2 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
5330000
CY2023Q4 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
4316000
CY2024Q2 ntra Accrued Interest
AccruedInterest
1078000
CY2023Q4 ntra Accrued Interest
AccruedInterest
1078000
CY2024Q2 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
2060000
CY2023Q4 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
2497000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
141231000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
149405000
CY2023Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
23245000
CY2022Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
18948000
ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
1065000
ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
5148000
ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
3095000
ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
963000
ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
4750000
ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
7653000
CY2024Q2 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
16465000
CY2023Q2 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
15480000
CY2024Q2 ntra Short Term Advances
ShortTermAdvances
13900000
ntra Noncash Operating Activities Related To Right Of Use Assets
NoncashOperatingActivitiesRelatedToRightOfUseAssets
600000
ntra Noncash Operating Activities Related To Right Of Use Assets
NoncashOperatingActivitiesRelatedToRightOfUseAssets
0
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12384000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11621000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61225000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
67025000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
73609000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
78646000
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.068
CY2024Q2 us-gaap Lease Cost
LeaseCost
3600000
CY2023Q2 us-gaap Lease Cost
LeaseCost
3700000
us-gaap Lease Cost
LeaseCost
7200000
us-gaap Lease Cost
LeaseCost
7500000
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
4100000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
3000000.0
us-gaap Operating Lease Payments
OperatingLeasePayments
8300000
us-gaap Operating Lease Payments
OperatingLeasePayments
5200000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
8449000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
17155000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
17450000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
14345000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6675000
CY2024Q2 ntra Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
27928000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
92002000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18393000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
73609000
CY2024Q1 us-gaap Loss Contingency Patents Allegedly Infringed Number
LossContingencyPatentsAllegedlyInfringedNumber
2
CY2024Q1 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
57000000
CY2024Q2 us-gaap Purchase Obligation
PurchaseObligation
103518000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67411000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
44312000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
131858000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
84789000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
892000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-282000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1320000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-122000
CY2024Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23213000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22568000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-011666-index-headers.html Edgar Link pending
0001558370-24-011666-index.html Edgar Link pending
0001558370-24-011666.txt Edgar Link pending
0001558370-24-011666-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ntra-20240630.xsd Edgar Link pending
ntra-20240630x10q.htm Edgar Link pending
ntra-20240630xex10d1.htm Edgar Link pending
ntra-20240630xex31d1.htm Edgar Link pending
ntra-20240630xex31d2.htm Edgar Link pending
ntra-20240630xex32d1.htm Edgar Link pending
ntra-20240630xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ntra-20240630_cal.xml Edgar Link unprocessable
ntra-20240630_def.xml Edgar Link unprocessable
ntra-20240630_pre.xml Edgar Link unprocessable
ntra-20240630_lab.xml Edgar Link unprocessable
ntra-20240630x10q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending